AbbVie Retained Earnings (Accumulated Deficit) 2010-2024 | ABBV

AbbVie retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $-7.900B, a 690% increase year-over-year.

  • AbbVie retained earnings (accumulated deficit) for 2024 were $-7.9B, a 690% increase from 2023.
  • AbbVie retained earnings (accumulated deficit) for 2023 were $-1B, a 120.9% decline from 2022.
  • AbbVie retained earnings (accumulated deficit) for 2022 were $4.784B, a 52.99% increase from 2021.

AbbVie Retained Earnings (Accumulated Deficit) 2010-2024 | ABBV

  • AbbVie retained earnings (accumulated deficit) for 2024 were $-7.9B, a 690% increase from 2023.
  • AbbVie retained earnings (accumulated deficit) for 2023 were $-1B, a 120.9% decline from 2022.
  • AbbVie retained earnings (accumulated deficit) for 2022 were $4.784B, a 52.99% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$823.1B
Johnson & Johnson (JNJ)$380.1B
Novo Nordisk (NVO)$374.3B
Roche Holding AG (RHHBY)$259.5B
Novartis AG (NVS)$218.5B
Merck (MRK)$216.5B
Pfizer (PFE)$146.7B
Sanofi (SNY)$136B
Bayer (BAYRY)$22B
Innoviva (INVA)$1.1B